John Somberg to Drug Approval
This is a "connection" page, showing publications John Somberg has written about Drug Approval.
Connection Strength
4.813
-
Conflating the approval process and clinical research with pharmacoeconomic evaluation. Am J Ther. 2013 Jan; 20(1):1.
Score: 0.443
-
Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
Score: 0.438
-
Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
Score: 0.433
-
Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
Score: 0.394
-
The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.
Score: 0.381
-
Supporting therapeutic innovation. Am J Ther. 2009 May-Jun; 16(3):203.
Score: 0.343
-
Off-label promotion. Am J Ther. 2006 Sep-Oct; 13(5):387.
Score: 0.285
-
Surrogate endpoints and drug approval. Am J Ther. 2006 Sep-Oct; 13(5):388.
Score: 0.285
-
Risk assessment, drug approval, and liability. Am J Ther. 2006 May-Jun; 13(3):181-2.
Score: 0.279
-
Nesiritide: the wrong controversy. Am J Ther. 2005 Sep-Oct; 12(5):377-8.
Score: 0.266
-
The new drug evaluation process: risk benefit ratio. Am J Ther. 2005 May-Jun; 12(3):199-200.
Score: 0.260
-
The provisional approval step. Am J Ther. 2005 Jan-Feb; 12(1):1-2.
Score: 0.254
-
Drug trial registries. Am J Ther. 2004 Sep-Oct; 11(5):327.
Score: 0.248
-
Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. Am J Ther. 1999 May; 6(3):175-8.
Score: 0.172
-
Sharing regulatory review costs. J Clin Pharmacol. 1992 Oct; 32(10):867.
Score: 0.109
-
Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
Score: 0.093
-
FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
Score: 0.079
-
Class effects of pharmaceuticals and therapeutic interchangeability. Am J Ther. 2001 Jul-Aug; 8(4):221-2.
Score: 0.050